Effects of tibolon on increased lipoprotein (a) levels by transdermal estradiol therapy

Öz

Objective: to evaluate the effects of tibolon on serum lipoprotein (a) levels in patients with surgical menopause . Materials and methods: Forty-sixpremenopausal women (mean age 42 ± 5,1) undergoing surgical menopause were included in the study and transdermal estradiol was started 10 days after surgery. Serum lipids including lipoprotein(a) were measured before and after the surgery for 1 year with 3 month- intervals. Tibolone was added to the therapy in patients with serum concentration of lipoprotein (a) greater than 30 mg/dl. Results: Thirty-five women were still under follow-up at the end of 12 months. In 19 of them lipoprotein(a) levels increased despite transdermal estradiol. Lipoprotein (a) level before transdermal estradiol therapy was 17,7 ± 7. Serum lipo¬protein (a) levels at the 3rd month, 6th month, 9th and 12th month of transdermal estrogen therapy were 33,1 ± 29,4, 54,6 ± 28,4 (p

Anahtar Kelimeler

• Lipoprotein(a),Estradiol,Tibolone,Androgen Antagonists,Menopause

Tibolonun transdermal östradiol tedavisiyle yükselmiş serum lipoprotein (a) düzeylerine etkisi

Öz

Amaç: Cerrahi menopozdaki hastalarda 17-â-östradiol ve tibolonun serum lipoprotein (a) düzeyi üzerindeki etkilerini değerlendirmek Materyal melod: Çalışmaya benign nedenlerle yapılan histerektomi ve bilateral salpingo-ooferektomi sonrası cerrahi menopoza giren 46 .olgu alındı. Çalışmaya alman tüm olgularda operasyon öncesi lipoprotein (a) seviyeleri ölçüldü. Olgulara postoperatif 10. gün transdermal 17- K-östradiol tedavisi başlandı. Bundan sonra bir yıl süre ile her üç ayda bir olguların lipoprotein (a), seviyelerine bakıldı. Takip sırasında serum lipoprotein (a) seviyesi 30 mg/dl üzerine çıkan hastaların tedavilerine tibolon eklendi. Bulgular: Transdermal östradiol başlamadan önce lipoprotein (a) seviyeleri ortalama 17.7 ±7 olarak ölçülürken 3 ay transdermal östradiol teda¬visi sonrasında ölçülen lipprotein(a) seviyeleri 33,1 ±29,4, 6 ay sonraki lipoprotein (a) seviyesi 54,6±28,4, 9.ay serum lipoprotein (a) seviyesi 43,0 ±8,9, 12.ayda lipoprotein (a) seviyesi 29,5 ±2,5 olarak ölçüldü. Tedavi öncesine göre 3,6,9 ve 12. aylardaki serum lipoprotein (a) seviyelerindeki artış anlamlı bulundu(p

Anahtar Kelimeler

• Lipoprotein(a),Östradiol,Tibolon,Androjen antagonistleri,Menopoz

Kaynakça

1. 1. Witteman J, Grobbe DE, Kok FJ, Hofman A, Valkenburg HA, Increased risk of atherosclerosis in women after the menopause. BMJ 1989; 298:642-5 2. Jackson G,Tibolone and the cardiovascular system. Eur Heart J Suppl 2001; 3: 16-21 3. Kannel WB, Hjortland MC, McNamara PM, Gordon T, Menopause and risk of cardiovascular disease. The Framingham Study. Ann Intern Med 1976; 85: 447-52 4. Kannel WB, Metabolic risk factors for coronary heart disease in women: perspective from the Framingham study. Am Heart J 1987; 114: 413-9 5. Mosca L, Manşon JE, Cardiovascular disease in women statement for healthcare profesionals from the American cardiovascular disease in women statement for healtcare professionals. American Heart Association Circulation. 1997; 96: 2468-82 6. Stampfer MJ, Estrojen replacement therapy and coronary heart disease a quantitative assesment of the epidemiologic evidence. Prev Med. 1991; 2047-63 7. Psaty BM, The risk of myocardial infartion associated with the combined use estrojen and progestin in postmenopausal women. Arch Inter Med 1994; 154: 1333-9 8. Grodstein F, Postmenopausal estrogen and progestin use and the risk of cardiovascular disease
2. N Engl J Med 1996; 335:453-61 9. Writing Group for the Women's Healt Initiative Investigators. Risks and Benefits of Estrogen Plus Progestin in Healty Postmenopausal Women. JAMA 2002; 288:321-33 10. Morrisett JD, The role of Hpoprotein(a) in atherosclerosis.Curr Atheroscler Rep 2000; 2(3):243-50
3. 11- Scanu A, Lipoprotein(a) heterogenety and biological relevance. J Clin Invest 1990, 85: 1709-1715 12-Uterman G, The mysteries of lipoprotein(a). Science 1989; 246:904-10 13. Wang S R, Changes in lipo(a) lipoprotein and lipid levels aftetr cessation of female sex hormone production and estrojen replacement therapy. Arch Intern Med 1996,156: 11 14. Brown SA, Plasma lipid lipoprotein kolesterol and apoprotein distribution in selected US communities the athersclerosis risk in communities study. Atheroscler Thromb Vase Biol 1993; 13: 1139-1158 15. Nabulsi AA, Association of hormone replacement therapy with varius cardiovacular risk factors in postmenopausal women. N Engl J.Med 1993; 15: 1069-75 16. Şendağ F, Karadadaş N., Effects of sequential combined transdermal and oral hormone replacement therapies on serum lipid and lipoproteins in postmenopausal women. Arch Gynecol Obstet 2002; 266:38-43 17. Meldrum DR, Biologic effects of transdermal estradiol. N Engl J Med 1986; 314:1615-20 18. Crook D, Comparison of transdermal and oral estrojen progestin replacement therapy effects of serum lipids and lipoproteins Am J Obstet Gynecol 1992; 166: 950-5 19. Speroff L, Internatonal consensus conference on postmenopausal hormone replacement therapy and the cardiovascular system. Fertil Steril 1994 ; 61: 592-5 20. Haenggi W, Reiesen W, Postmenopausal hormone replacement therapy with tibolone decerases serum lipoprotei(a). Eur J Clin Chem Clin Biochem 1993;31: 645-50 21. Rymer J, Crook. D, Effects of tibolone on serum concentrations of lipoprotein (a) in postmenopausal women. Acta Endocrinol 1993; 128(3): 259-62 22. Moliterno DJ, Jokınen E.V., MserezA.R., et all: No association between plazma lipoprotein (a) concentrations and precence or absence of coronary atherosclerosis in African Americans. Arterioscler Thromb Vase Biol 1995; 15: 850-85, 23. Haenggi W, Reiesen W, Postmenopausal hormone replacement therapy with tibolone decerases serum lipoprotein (a) Eur J Clin Chem Clin Biochem 1993,31: 645-650 24. Haeggi W., Lippuner K, Long term influence of diferent postmenopausal hormone replacement regimens on serum lipids and lipoprotein (a): a randomised study Br J Obstet Gynaecol. 1997; 7:108-117 25. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondery prevention of coronory heart disease in postmenopausal women. JAMA 1998; 280: 613
4. 26. Chetkowski RJ Biological effects of transdermal estradiol. N Engl J Med 1986; 314: 1615-20 27. Grady D, Herrington D, Bittner V, ve ark. for the HERS Research Group. Cardiovasculer disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin DReplacement Study Follow-up (HERS II). JAMA 2002 ; 288: 49-57
5. 28. İrican M, Sarandöl E, Uncu G, ve ark. Postmenopozal Kadınlarda Tibolon ve Transdermal Östrojen Kullanımının Lipid Düzeylerine ve Apolipoprotein B-İçeren Lipoproteinlerin Oksidasyonuna Etkisi. Jinekoloji ve Obstetrik Dergisi 1999; 13:202-207
6. 29. Şan K, Api M, Unsal M, ve ark. Cerrahi Menopozda Kullanılan Konjuge Östrojen,Transdermal Östradiol ve Tibolonun Lipid Profili ve Kardiyovasküler Risk Üzerine Etkileri. Jinekoloji ve Obstetrik Dergisi 1999; 13: 30-35